These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 25165180

  • 1. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
    Verhave JC, Wetzels JF, van de Kar NC.
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv131-41. PubMed ID: 25165180
    [Abstract] [Full Text] [Related]

  • 2. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR, Johnson S.
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [Abstract] [Full Text] [Related]

  • 3. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring.
    Mannucci PM, Cugno M.
    Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489
    [Abstract] [Full Text] [Related]

  • 4. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
    Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC.
    Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
    [Abstract] [Full Text] [Related]

  • 5. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M, Mescia F, Remuzzi G.
    Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
    [Abstract] [Full Text] [Related]

  • 6. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.
    Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, Hélou S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C.
    Nephrol Dial Transplant; 2014 Mar; 29(3):565-72. PubMed ID: 24293658
    [Abstract] [Full Text] [Related]

  • 7. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U, Matar RB, Rotz SJ.
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [Abstract] [Full Text] [Related]

  • 8. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J.
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [Abstract] [Full Text] [Related]

  • 9. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M, Tanabe K.
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [Abstract] [Full Text] [Related]

  • 10. Thrombotic microangiopathies.
    Rosove MH.
    Semin Arthritis Rheum; 2014 Jun; 43(6):797-805. PubMed ID: 24360024
    [Abstract] [Full Text] [Related]

  • 11. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J.
    Nephrol Dial Transplant; 2020 Dec 04; 35(12):2147-2153. PubMed ID: 31411695
    [Abstract] [Full Text] [Related]

  • 12. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
    Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD.
    Nephrology (Carlton); 2018 Jun 04; 23(6):507-517. PubMed ID: 29419916
    [Abstract] [Full Text] [Related]

  • 13. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P, Netti GS, Santangelo L, Castellano G, Carbone V, Torres DD, Martino M, Sesta M, Di Cuonzo F, Resta MC, Gaeta A, Milella L, Chironna M, Germinario C, Scavia G, Gesualdo L, Giordano M.
    Pediatr Nephrol; 2019 Mar 04; 34(3):517-527. PubMed ID: 30362078
    [Abstract] [Full Text] [Related]

  • 14. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG, Kirsztajn GM.
    J Bras Nefrol; 2010 Mar 04; 32(3):303-15. PubMed ID: 21103695
    [Abstract] [Full Text] [Related]

  • 15. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.
    Derad I, Obermann B, Katalinic A, Eisemann N, Knobloch JK, Sayk F, Wellhöner P, Lehnert H, Solbach W, Süfke S, Steinhoff J, Nitschke M.
    Nephrol Dial Transplant; 2016 Jan 04; 31(1):95-103. PubMed ID: 26180049
    [Abstract] [Full Text] [Related]

  • 16. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr 04; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

  • 17. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.
    Nefrologia; 2015 Apr 04; 35(5):421-47. PubMed ID: 26456110
    [Abstract] [Full Text] [Related]

  • 18. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.
    de Zwart PL, Mueller TF, Spartà G, Luyckx VA.
    Pediatr Nephrol; 2024 May 04; 39(5):1369-1385. PubMed ID: 38057431
    [Abstract] [Full Text] [Related]

  • 19. [Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].
    Casiez C, Pica GM, Bally S.
    Nephrol Ther; 2020 Jul 04; 16(4):221-224. PubMed ID: 32571738
    [Abstract] [Full Text] [Related]

  • 20. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
    de Ville de Goyet M, Detaille T, Godefroid N.
    J Pediatr Hematol Oncol; 2019 Oct 04; 41(7):e459-e462. PubMed ID: 30933023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.